IQVIA Holdings Inc
$ 224.92
-1.02%
04 Dec - close price
- Market Cap 38,698,971,000 USD
- Current Price $ 224.92
- High / Low $ 227.53 / 214.01
- Stock P/E 31.04
- Book Value 36.17
- EPS 7.32
- Next Earning Report 2026-02-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.19 %
- 52 Week High 234.30
- 52 Week Low 134.65
About
IQVIA Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services specifically focused on the healthcare industry. Born from the merger of Quintiles and IMS Health, the company specializes in biopharmaceutical development and commercial outsourcing, providing extensive support for all phases of clinical trials and laboratory services. Leveraging cutting-edge data and technology, IQVIA is dedicated to fostering innovation and improving patient outcomes, positioning itself as a transformative force in the global healthcare landscape. With a strong emphasis on quality and efficiency, the company is well-equipped to meet the evolving needs of its clients in a complex and dynamic market.
Analyst Target Price
$250.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-22 | 2025-05-06 | 2025-02-06 | 2024-10-31 | 2024-07-22 | 2024-05-02 | 2024-02-14 | 2023-11-01 | 2023-08-01 | 2023-04-27 | 2023-02-10 |
| Reported EPS | 3 | 1.54 | 2.7 | 2.42 | 1.55 | 2.64 | 2.54 | 2.84 | 2.49 | 2.43 | 2.45 | 2.78 |
| Estimated EPS | 2.97 | 1.73 | 2.63 | 2.09 | 1.92 | 2.57 | 2.48 | 2.82 | 2.44 | 2.37 | 2.41 | 2.76 |
| Surprise | 0.03 | -0.19 | 0.07 | 0.33 | -0.37 | 0.07 | 0.06 | 0.02 | 0.05 | 0.06 | 0.04 | 0.02 |
| Surprise Percentage | 1.0101% | -10.9827% | 2.6616% | 15.7895% | -19.2708% | 2.7237% | 2.4194% | 0.7092% | 2.0492% | 2.5316% | 1.6598% | 0.7246% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 3.39 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IQV
2025-12-04 15:48:50
Thermo Fisher Scientific (TMO) has seen its share price rise by 3% in the last month and 18% over three months, prompting a reevaluation of its valuation. Despite trading below analyst targets, the company's strong innovation in analytical tools and AI integration positions it for future revenue and margin growth. While a narrative suggests it is 5.4% undervalued, risks such as persistent weakness in China or funding pressures could impact its performance.
2025-12-04 12:09:54
Panagora Asset Management Inc. significantly increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by acquiring an additional 80,323 shares, raising its total holdings to 87,917 shares valued at $13.86 million. This move comes alongside other institutional investment changes and a recent insider stock sale by Eric Sherbet. Analyst sentiment remains generally positive for IQVIA, with an average "Moderate Buy" rating and a target price of $241.44.
2025-12-04 07:11:17
IQVIA Holdings Inc. (IQV) is trading 3% below its 52-week high after reporting strong Q3 2025 financial results, with revenue up 5.2% and adjusted EPS up 5.6% year-over-year. The stock has surged 23.1% in the past three months, outperforming the S&P 500, and analysts have a "Strong Buy" consensus rating with a 7.4% upside potential.
/IQVIA%20Holdings%20Inc%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
2025-12-04 05:09:19
IQVIA Holdings (IQV) has shown strong performance recently, with its stock soaring 23.1% in the past three months, significantly outpacing the S&P 500. While its year-to-date and 52-week gains have slightly lagged the broader market, the company's Q3 results exceeded expectations, driven by organic revenue growth. Analysts currently rate IQV as a "Strong Buy" with a potential 7.4% upside.
/IQVIA%20Holdings%20Inc%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
2025-12-04 03:54:07
IQVIA Holdings Inc. (IQV) is a large-cap company providing clinical research and healthcare intelligence. The stock has outperformed the S&P 500 over the past three months and analysts rate it a "Strong Buy." Despite lagging the broader market over the past year, IQVIA reported strong Q3 results, beating revenue and EPS expectations.
2025-12-04 03:32:00
IQVIA Holdings Inc. (IQV) has shown strong performance in the short term, with its stock soaring 23.1% over the past three months, outperforming the S&P 500's 6.2% gains. The company, valued at $38.4 billion, exceeded Q3 earnings expectations and boasts a "Strong Buy" consensus rating from analysts. While slightly lagging the broader market over longer periods, IQV demonstrates a bullish trend and significant upside potential.
